FORM PTO-1449 (REV.7-80)	9	· · · · · · · · · · · · · · · · · · ·	U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. PATENT AND TRADEMARK OFFICE 210121.465C2 APPLICATION NO. 09/684,361								PE
INF	ORM	ATIO	ON DISCLOSU	RE STATEM	ENT	APPLICANTS Alexander Gaiger and	d Mar	tin A	. Cheever	/ 0 ·	
		(Us	e several sheets if ne	cessary)		FILING DATE October 6, 2000		GRO	UP ART UNIT	JAN	1 6 2001
				ILS	PATENT I	DOCUMENTS		<u>. </u>		E.	6
*EXAMINER		DO	CUMENT NUMBER	DATE		NAME	CLA	SS	SUBCLASS	FILING	DATE
INITIAL OF (0-11-4-1		526		if APPROPRIAT		
Ph	AA	3,3	550,840	09/27/94	Call et al.		536		23.1		
	ı ·	1	DOGUD COM	FOREI	GN PATEN	T DOCUMENTS				TRANS	LATION
1295			DOCUMENT NUMBER	DATE		COUNTRY				YES	NO
j	AB	W	/O99/58135	11/18/99	PCT V	0.0					
	AC	W	/O95/29995÷	11/09/95	PCT W	0					
	AD	W	/O95/06725	03/09/95	P CT w	0	-				
4	AE	W	O 91/07509	05/30/91	PCT W						
			ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.				-
100 /	AF		Aaronson and	d Todaro, "I	Developme	nt of 3t3-like lines from	n Balt	o/c m			
11/2)			transformatio	on susceptib	ility to SV4	0," J. Cell. Physiol. 72	?(2):14	41-14	18, Octobe	r 1968	•
	AG		Adachi et al., (WT1)," Onc			arget gene for the Wiln 1996.	ıs' tur	nor s	suppressor	gene	
-			A 1 . 1 . 6	(A XX / TC 1	• ••	1 1 . 1 . 1	1.0	 	1 • 1		<u> </u>
	AH					onucleotide inhibits pro occogene 12: 1005-1014			and induce	s apop	tosis
					,		,				
	AI		_	-	•	f the Wilms' tumour ge of Development 40: 85-			in the deve	eloping	3
			manimanan c	inioryo, <i>m</i>	ecnanisms (n Development 40. 63.	-77, 1	77 2.			
	AJ					ation of leukemic prog					
			specific for V	VILMS Tun	nor Antigen	-1 (WT-1)," <i>Blood, 94</i>	(10):5)32A	-533A, No	vembe	er 15,
	AK					ilms' Tumor Gene (wt					
			Leukemias A 1997.	are Associate	ed With a V	Vorse Long-Term Outo	ome,	Blo	oa 90(3): 1	1217-1	225,
	AL		-			ne Expression in Acute	Муе	loid	Leukemias	,"	-
1			Leukemia an	d Lymphom	a 25: 435-4	43, 1997.					
EXAMINE	R	$\sqrt{\Lambda}$	11			DATE CONSIDERED	200 7			_	
* EXAMIN	ER:	Initial	if reference conside	red. whether or no	ot criteria is in co	nformance with MPEP 609. Dra			citation if not in		

conformance and not considered. Include copy of this form with next communication to applicant(s).

FÖRM PTO-1449 (REV.7-80)											
INFO	ORM.	ATI(ON DISCLOSU	RE STATEM	ENT	APPLICANTS Alexander Gaiger and	d Mar	tin A	. Cheever	10	PE
			e several sheets if ne			FILING DATE October 6, 2000			UP ART UNIT	MAL	1 6 5001
				U.S.	PATENT I	DOCUMENTS				EXT.	.63
*EXAMINER INITIAL		DO	CUMENT NUMBER	DATE		NAME	CLA	ss	SUBCLASS	FILE IF APPR	DATE OPRIATE
	ВА										
				FOREI	GN PATEN	NT DOCUMENTS				_	
			DOCUMENT DATE NUMBER			COUNTRY				YES	NO NO
	ВВ										
			ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.)			
V35	вс					ain reaction detects dit in Wilms' tumors," C				33, 199	92.
	BD			Brieger et al., "The Expression of the Wilms' Tumor Gene in Acute Myelocytic Leukemias as Possible Marker for Leukemic Blast Cells," <i>Leukemia</i> 8(12): 2138-2143, 1994.							
	BE			d may provi	de a marke	ene is frequently expre or for residual blast cell					als of
V	BF					zation, and Expression pment," Molecular and					
	ВG					zation of a Zinc Finger cus," Cell 60: 509-520,			ide Gene a	t the H	uman
	ВН			frequent in		mutations of the Wilm crisis and de novo acut					
	BI			renal tumou		ilms' tumour gene WT unohistochemical stud					
	ВЈ					al detection of the Wil ur," Histopathology 30				Γ1 in	
V	вк					py can be obtained from 065-1070, February 15			loaded spo	onge	
EXAMINI	ER /		() ~			DATE CONSIDERED	_	_	-		
* EXAMIN	ER:	Initia	I if reference conside	red, whether or no	ot criteria is in co	onformance with MPEP 609. Dra		rough	citation if not in	n	

conformance and not considered. Include copy of this form with next communication to applicant(s).

•							5	Sheet 3	of <u>13</u>
FORM PTO-14 (REV.7-80)	49		S. DEPARTMENT ATENT AND TRAD		ATTY. DOCKET NO. 210121.465C2		PLICATION NO. 9/684,361		
INF	ORM	ATION DISCLOSU		ENT	APPLICANTS Alexander Gaiger and	d Martin	A. Cheever		5111
		(Use several sheets if no	ecessary)		FILING DATE October 6, 2000	GR ,	OUP ART UNIT	F 1	AN 1 B
			U.S.	. PATENT I	DOCUMENTS			E.	·
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPR	DATE OPRIATE
	CA		500						
·		T	FOREI	GN PATEN	T DOCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY			TRANS YES	LATION NO
7.1.	СВ							_	
		ОТНЕ	CR PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.)			
ms	СС		duction in a	group of m	Ta8 antigen, THY-1.2 purine virus-induced le October 1976.				
	CD	Deavin et al.	"Statistical	comparison	n of established T-cell ens," Molecular Immu				
	CE		allows the i	induction of	empty major histocom primary cytotoxic T l per 1991.				
	CF	Drummond e	t al., "Repre	ssion of the	Insulin-Like Growth 57: 674-677, 1992.	Factor Ge	ene by the V	Vilms	
	CG				on 1.1) A computer prothms," Nature 349: 720			cell	
	СН	Foster et al., adenocarcino 3330, August	ma of the m	vation of pro ouse prosta	ostatic epithelial cell linte (TRAMP) model," (nes derive Cancer R	ed from trar esearch 57(nsgenic 16):33	25-
	CI				nor Suppressor Gene V 6, 1995 (letter).	VT1 in B	oth Human	and M	ouse
	CJ				a and cancer antigen A for Cancer Research,			: Annu	al
	ск	Gaiger et al., 94(10):78, No			nimal models and leuk	kemia pat	eints," Bloo	od,	

EXAMINER

N C

DATE CONSIDERED 2/11/2003

* EXAMINER:

FORM PTO-1449 (REV.7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. 210121.465C2 APPLICATION NO. 09/684,361

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Alexander Gaiger and Martin A. Cheever

FILING DATE GROUP ART UNIT October 6, 2000 U.S. PATENT DOCUMENTS *EXAMINER FILING DATE **SUBCLASS** DOCUMENT NUMBER DATE NAME CLASS INITIAL IF APPROPRIATE DA FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY NUMBER YES DB OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Gaiger et al., "Immunity to WT1 in the animal model and in patients with acute myeloid DC leukemia," Blood 96(4):1480-1489, August 15, 2000. Gillis and Smith, "Long term culture of tumour-specific cytotoxic T cells," Nature DD 268:154-156, July 14, 1977. Glynn et al., "Cross-resistance to the transplantation of syngeneic friend, moloney, and DE rauscher virus-induced tumors," Cancer Research 28(3):434-439, March 1968. Goodyer et al., "Repression of the retinoic acid receptor-α gene by the Wilms' tumor DF suppressor gene product, wt1," Oncogene 10: 1125-1129, 1995. Haber et al., "A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral DG oncogene E1A in transformation of primary kidney cells," Proc. Natl. Acad. Sci. USA 89: 6010-6014, 1992. Haber et al., "Alternative splicing and genomic structure of the Wilms tumor gene WT1," DΗ Proc. Natl. Acad. Sci. USA 88: 9618-9622, 1991. Haber et al., "An Internal Deletion within an 11p13 Zinc Finger Gene Contributes to the DI Development of Wilms' Tumor," Cell 61: 1257-1269, 1990. Hamilton et al., "High affinity binding sites for the Wilms' tumour suppressor protein DJ WT1," Nucleic Acids Research 23(2): 277-284, 1995. Harrington et al., "Inhibition of Colony-stimulating Factor-1 Promoter Activity by the DK Product of the Wilms' Tumor Locus," The Journal Of Biological Chemistry 268(28): 21271-21275, 1993. **EXAMINER DATE CONSIDERED**

* EXAMINER:

•								S	Sheet <u>5</u>	of <u>13</u>
FÓRM PTO-14 (REV.7-80)	19		J.S. DEPARTMENT ATENT AND TRAD		ATTY. DOCKET NO. 210121.465C2			LICATION NO. 684,361		OIP
INF	ORM	ATION DISCLOSU		1ENT	APPLICANTS Alexander Gaiger and	d Mar	t <u>in A</u>	. Cheever	\mathcal{L}	.u 1.6
		(Use several sheets if ne	cessary)		FILING DATE October 6, 2000		GRO	UP ART UNIT	ET.	Pile
			U.S	. PATENT	DOCUMENTS				₹€	TRAD:
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	ss	SUBCLASS		G DATE OPRIATE
	EA									
	· r	Ţ	FORE	IGN PATEN	NT DOCUMENTS					
		DOCUMENT NUMBER	DATE		COUNTRY				TRANS YES	NO
	ЕВ									
		ОТНЕ	ER PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.,)			
psy	EC	Harrington et al., "Inhibition of Colony-stimulating Factor-1 Promoter Act Product of the Wilms' Tumor Locus," <i>The Journal Of Biological Chemistr</i> 21271-21275, 1993.						•	•	;
	ED	Horibata and Research 60:			mas and lyphomas in c	ulture	," Ex	:perimenta	l Cell	
	EE			-	al, and Tumor-Specific ace 250: 991-994, 1990	-	essio	n of Diver	gent	
	EF	Inoue et al., ' Leukemia," I		-	on of the Wilms Tumo 2, 1997.	r Gen	e (W	T1) in Hu	man	
	EG		_	-	o of Minimal Residual Ine) Expression Levels,					-
	ЕН				WT1) Competes With 1 Blood 91(8): 2969-297			tion-Induc	ing Si	gnal
	EI				stic Factor and a New Material				ion of	
	EJ		cute Myeloid		es, "Wilms' Tumor (Wand May Confer Drug					
	EK	King-Underw		'Mutations	in the Wilms' Tumor C	Gene V	VT1	in Leukem	nias," I	Blood

* EXAMINER:

EXAMINER

•				·	·		S	heet 6	of <u>13</u>	
FÖRM PTO-144 (REV.7-80)	9		S. DEPARTMENT TENT AND TRAD		ATTY. DOCKET NO. 210121.465C2		application no. 09/684,361		OIP	
INF	ORM	ATION DISCLOSU	RE STATEM	ENT	APPLICANTS Alexander Gaiger and Martin A. Cheever					
		(Use several sheets if ne	cessary)		FILING DATE October 6, 2000		GROUP ART UNIT	ELECT	<u>.</u>	
			U.S.	PATENT I	DOCUMENTS			-	TRA	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLAS	S SUBCLASS		G DATE OPRIATE	
	FA									
			FOREI	GN PATEN	NT DOCUMENTS					
-		DOCUMENT NUMBER	DATE		COUNTRY			TRANS YES	LATION NO	
	FB									
		ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent P	ages, Etc.)				
PSS	FC	Kreidberg et 1993.	al., "WT-1 l	ls Required	for Early Kidney Dev	velopme	nt," <i>Cell 74</i> : 6	579-69	1,	
	FD		ırcinoma cel	lls induces a	on of the Wilms tumor apoptotic cell death in		_		9	
	FE				ed by Wilms tumor pr . Acad. Sci. USA 92: 4			ed by		
	FF	Kwok and Hi 1989.	guchi, "Avo	oiding false	positives with PCR,"	Nature	<i>339</i> :237-238,	May 1	18,	
	FG		•		tion of WT1 in Splicing," Cell 81: 3	_	-	octor		
	FH	Ljunggren et 480, August 2		MHC class	s I molecules come ou	t in the	cold," Nature	346:4	76-	
	FI				myelogenous leukem 5(3):321-334, March		ine with posit	ive		
	FJ	Luo et al., "T Oncogene 11			ene WT1 inhibits <i>ras-</i> r	nediated	d transformati	on,"	···	
	FI.	Madden et al.	., "Transcrip	tional Repr	ression Mediated by th	ne WT1	Wilms Tumo	r Gene	;	

* EXAMINER:

EXAMINER

FΚ

DATE CONSIDERED ンしゃしいろ Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Product," Science 253: 1550-1552, 1991.

FÖRM PTO-1449
(REV.7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 210121.465C2 0

PPLICATION NO.	
9/684,361	6

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS Alexander Gaiger and Martin A. Cheever

GROUP ART UNIT FILING DATE October 6, 2000

-				Uci	ober 6, 2000			13	
			U.S.	. PATENT DOC	UMENTS			K.	TRAD
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	N	NAME CLA:		SUBCLASS	FILIN	G DATE OPRIATE
	GA								
			FOREI	GN PATENT D	OCUMENTS				- - -
		DOCUMENT NUMBER	DATE		COUNTRY			TRANS	LATION
	GB								
	·	OTHE	CR PRIOR A	RT (Including Author	, Title, Date, Pertinent	Pages, Etc.)			
Wy	GC		ed early in th	ns' tumor gene is the course of diff	-				
	GD		Menke et al., "Wilms' Tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells," <i>Oncogene 12</i> : 537-546, 1996.						
	GE		Menssen et al., "Detection By Monoclonal Antibodies Of The Wilms' Tumor (WT1) Nuclear Protein In Patients With Acute Leukemia," Int. J. Cancer 70: 518-523, 1997.						
	GF			e of Wilms' tum human acute le	• '	-			ır
	GG		Ouring Fetal	Tumor Gene Ex Development a			_		3486-
	GН		'Expression	of the Wilms' T 1992.	umor Gene (W	T1) in Hum	an Leukem	ias,"	
	GI	1	-	n of the Candida nia 7(7): 970-97		or Gene, W	T1, in Hum	an	
	GJ			zation of the zin 6: 2339-2348, 1		encoded by	the WT1	Wilms)
1	GK			localization of the dult tissues," De				or gen	e

EXAMINER * EXAMINER: DATE CONSIDERED

	·
FORM PTO-1449	U.S. DEPARTMENT OF CO
(REV.7-80)	PATENT AND TRADEMAR
INFORMATION	ICCI OCUDE CE LEDICENE
INFURMATION D	ISCLOSURE STATEMENT

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

(Use several sheets if necessary)

ATTY. DOCKET NO. 210121.465C2 APPLICATION NO. 09/684,361

APPLICANTS

Alexander Gaiger and Martin A. Cheever

FILING DATE October 6, 2000 GROUP ART UNIT

1AN 1 6 2001

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	НА		-				
			FOREI	GN PATENT DOCUMENTS			

		DOCUMENT	DATE	COUNTRY	TRANS	
		NUMBER	DAIL	COUNTRI	YES	NO
	НВ					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

place	НС	Murata et al., "The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells," FEBS Letters 409: 41-45, 1997.
	HD	Nakagama et al., "Sequence and Structural Requirements for High-Affinity DNA Binding by the WT1 Gene Product," <i>Molecular and Cellular Biology</i> 15(3): 1489-1498, 1995.
	HE	Nichols et al., "WT1 Induces Expression of Insulin-like Growth Factor 2 in Wilms' Tumor Cells," Cancer Research 55: 4540-4543, 1995.
	HF	Ogawa et al., "Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay," Bone Marrow Transplantation 21: 525-527, 1998.
	HG	Old et al., "Antigenic properties of chemically induced tumors," <i>Annals of the New York Academy of Sciences 101</i> :80-107, November 20, 1962.
	нн	Osaka et al., "WT1 Contributes To Leukemogenesis: Expression Patterns In 7,12-Dimethylbenz[a]Anthracene (DMBA)-Induced Leukemia," <i>International Journal of Cancer 72</i> : 696-699, 1997.
	н	Parker et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>Journal of Immunology 152</i> : 163-175, 1994.
	нл	Patek et al., "Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis," <i>Nature 276</i> :510-511, November 30, 1978.
4	нк	Patmasiriwat et al., "Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities," <i>Leukemia 10</i> : 1127-1133, 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER:

	•
FORM PTO-1449	U.S. DEPARTMENT OF CO
(REV.7-80)	, PATENT AND TRADEMARI
INFORMATION	I DICCI OCUBE CTATEMENT
	N DISCLOSURE STATEMENT

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

. ATTY. DOCKET NO. 210121.465C2 APPLICATION NO.

09/684,361

APPLICANTS

Alexander Gaiger and Martin A. Cheever

GROUP ART UNIT

(Use several sheets if necessary) FILING DATE

				Octo	ber 6, 2000			V	
FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY Tourn Suppressor Gene Are Associated with Abnormal Urogenital Development in Denys-Drash Syndrome," 437-447, 1991. Pellean et al., "Germline Mutations in the Wilms' Tumor Suppressor Gene Are Associated with Abnormal Urogenital Development in Denys-Drash Syndrome," 437-447, 1991. IE Phelan et al., "Wilms' Tumor Gene, WT1, mRNA Is Down-regulated during Inductive Erythroid and Megakaryocytic Differentiation of K562 Cells," Cell Growth & Differentiation 5: 677-686, 1994. IF Pogue et al., "Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity," Proc. Natl. Acad. Sci. USA 92: 8166-8170, 1995. Pritchard-Jones et al., "The candidate Wilms' tumour gene is involved in genitour development," Nature 346: 194-197, 1990. Pritchard-Jones et al., "The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient," Human Molecular Genetics 3(9): 1633-1637, 199					WAN.	BADEN			
1 I TWY TIMENT NITMORE			DATE NAME		CLASS		EII DIC D		
	IA								
			FORE	GN PATENT DO	CUMENTS		J	<u>L </u>	
	Π			1					LATION
	ID	NUMBER						YES	NO
	IB							<u> </u>	<u> </u>
	<u> </u>								
Mz	IC					I in the m	urine uroge	enital	
	ID	Associated w	ith Abnorm						! 67:
	IE	Erythroid and	l Megakary	ocytic Differentia				luction	ı of
	IF	immunodefic	iency virus	pol peptide incre	ases complex sta	ability and			
	IG	Pritchard-Jon	es et al., "T	he candidate Wil	ns' tumour gene		ed in genito	ourinar	у
	IH								
	II		_	on of the Wilms' rowth & Different			_	Mouse	
	נו			e Expression Patt diatric Renal Tun					
d	IK			of the Wilms' To cience 250: 1259-		c Finger Pi	rotein to the	e EGR	-1
EXAMINE	IR			DAT	CONSIDERED				-

* EXAMINER:

FORM PTO-144 (REV.7-80)	19		S. DEPARTMENT O		E 010101 46500 00/604 261 -					
(APPLICANTS	0:	7/064,301	/0	IPE		
INF	ORM	ATION DISCLOSU	RE STATEMI	ENT	Alexander Gaiger and	d Martin	A. Cheever			
		(Use several sheets if ne	cessary)		FILING DATE	GR	OUP ART UNIT	TO JAN	164	
					October 6, 2000			B		
			U.S.	PATENT I	DOCUMENTS			FILING	BAC M	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	DATE PRIATE	
	JA									
	<u>.</u>		FOREIG	GN PATEN	NT DOCUMENTS		<u> </u>			
		DOCUMENT	DATE		COUNTRY	<u> </u>		TRANSL	ATION	
		NUMBER	DAIL		COONIKI	-		YES	NO	
	JВ									
		ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.)				
1000	1C				gene product: a develor					
123		transcription 903, 1993.	factor in the	kidney tha	t functions as a tumor	suppress	or," <i>FASEB</i>	J. 7: 8 9	96-	
			ıl "Characte	erization of	monoclonal antibodie	s directed	d to the amir	no-term	inus	
]D		•		or," Hybridoma, 17(2)					
					, , , , , , , , , , , , , , , , , , , ,					
	JWE		Reddy et al., "WT1-mediated Transcriptional Activation Is Inhibited by Dominant							
		Negative Mu 1995.	tant Proteins	," The Jou	rnal Of Biological Che	mistry 2	70(18): 1087	/8-1088	34,	
			l Taylor. "A	sequence n	eattern common to T ce	ell eniton	es." <i>EMBO</i> .	Journa	1.	
	JF	7(1):93-100,	<u>-</u>	poquemet p		n opnop	55, 2.772 5		,	
	JG				or Suppressor Gene W.					
		Autoregulate	a, <i>The Jour</i>	паі Ој Біоі	logical Chemistry 269(8): 0198	-0200, 1994	•		
	ЈН	Sadovnikova	et al., "Gene	ration of h	uman tumor-reactive c	ytotoxic	T-cells agai	nst pep	tides	
	Jn	1			olecules," Eur.J. Immi	•	_		İ	
	JI	1	chmid et al., "Prognostic significance of WT1 gene expression at diagnosis in adult de							
		novo acute m	yeloid leuke	mia," <i>Leuk</i>	temia 11: 639-643, 199	97.			ļ	
		Sekiya et al.,	"Downregul	ation of W	ilms' Tumor Gene (wt	1) Durin	g Myelomor	nocytic		
	111	_	_		od 83(7): 1876-1882, 19	•		•		
	-		//> · · · · ·							
<i>t</i>	JK	l l		_	f Rat Wilms' Tumor C	-	•			
`		Research 52:			n in the Urogenital Sys	stem and	i die Brain,	Cancel		
EXAMINI	ER	Λ /	0107 0112,	1772.	DATE CONSIDERED			-		
		VL			2/19/200	>				
* EXAMIN					nformance with MPEP 609. Draw with next communication to appli	v line throug	h citation if not in			

								Sheet 11	l of 13
FORM PTO-144 (REV.7-80)	19	-	U.S. DEPARTMENT PATENT AND TRAD				APPLICATION NO 09/684,361	0.	OIPE
INF	ORM	IATION DISCLOSU		1ENT	APPLICANTS Alexander Gaiger and		-	er ,	1AN 1 6
		(Use several sheets if ne	ecessary)		FILING DATE October 6, 2000		GROUP ART UNI	展	3F4+
			U.S	. PATENT	DOCUMENTS			₹	PADI
*EXAMINER INITIAL	I I DENTINALNE NUMBER I DATE I			NAME	CLAS	SS SUBCLAS	``	NG DATE PROPRIATE	
	KA			<u></u>				<u> </u>	
			FORE	IGN PATEN	NT DOCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY			TRANS YES	ISLATION NO
	КВ								
		ОТНІ	ER PRIOR A	ART (Including	g Author, Title, Date, Pertinent Pa	ages, Etc.)			
MS	KC	1 1		•	on of the WT1 Wilms to i. USA 94: 8132-8137,		uppressor ge	ene in hu	ıman
	KD	I h	ase antigens o	of Mycoba	and immunological evacterium tuberculosis,"		-		creted
	KE				nurine B-cell leukaemia	a," <i>Nat</i> 1	ure 272:624	-626, Ar	pril
	KF				ssion of the Wilms' tur fferentiation program,"				kemic
	KG	Tadokoro et : 83: 1198-120		ic Organiza	ation of the Human WI	[1 Gen	e," <i>Jpn. J. C</i>	ancer R	es.
	КН	Tadokoro et a Oncogene 7:	_	-	gous deletion of the W	T1 gen	ie in Wilms'	tumor,"	,
	KI	Tadokoro et a Molecular G			9 Polymorphisms in th 06, 1993.	e WT1	Gene," Hur	nan	,
	ĸ	Tadokoro et a 19(9): 2514,	_	FLPs at the	Wilms' tumor gene (W	VT1),"	Nucleic Aci	ds Resec	arch
	KK	Telerman et a (WT1) gene,"			ne cellular protein encod 48, 1992.	ded by	the human	Wilms' t	umor

EXAMINER

DATE CONSIDERED

2/19/2103

* EXAMINER:

FORM PTO-1449 (REV.7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 210121.465C2 APPLICATION NO.

09/684,361

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS Alexander Gaiger and Martin A. Cheever

FILING DATE October 6, 2000 GROUP ART UNIT

U.S.	PATE:	NT DO	CUMENTS

			0.0.					-OLL
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPR	DATE OPRIAT
	LA							
			FOREI	GN PATENT DOCUMENTS				
		DOCUMENT DATE COUNTRY					TRANS YES	LATIOI NO
-	LB							
,		ОТНЕ	R PRIOR A	RT (Including Author, Title, Date, Pertinent Pa	ges, Etc.)			
My	rc	i		nor eradication by adoptively tran <i>Cancer</i> , 66:686-691, 1996.	sferred cy	totoxic T-c	ell clo	nes i
	LD			cloning and developmental expres 15-220, 1998.	sion of the	e porcine h	omolo	gue
	LE			ranscriptionally active DNA-bindi oc. Natl. Acad. Sci. USA 90: 8896-			s tumoi	r
	LF	_	through Se	'Tumor Gene Product WT1 Active parate Functional Domains," <i>The</i> -9175, 1993.			al	
	LG	_	ed Growth	'Tumor Gene Product, WT1, Rep Factor A-chain Gene," <i>The Journa</i> 992.		-		
	LH	_		Vilms' tumor suppressor gene proclear protein," <i>Oncogene 10</i> (6): 1	-		cription	1

LK

LI

IJ

Werner et al., "Inhibition of Cellular Proliferation by the Wilms' Tumor Suppressor WT1 Is Associated with Suppression of Insulin-Like Growth Factor I Receptor Gene Expression," Molecular and Cellular Biology 15: 3516-3522, 1995.

Watson et al., "Leukemia viruses associated with mouse myeloma cells," Proceedings of

Wu et al., "GATA-1 Transactivates the WT1 Hematopoietic Specific Enhancer," The Journal Of Biological Chemistry 270(11): 5944-5949, 1995.

EXAMINERL

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

the National Academy of Sciences 66(2):344-351, June 1970.

CUMENT NUMBER DOCUMENT NUMBER OTHE Yamagami et	U.S. PATENT	APPLICANTS Alexander Gaiger and FILING DATE October 6, 2000 DOCUMENTS NAME ENT DOCUMENTS COUNTRY	l Martin A		JAN JAN			
DOCUMENT NUMBER DOCUMENT NUMBER OTHE Yamagami et	U.S. PATENT DATE FOREIGN PATE	FILING DATE October 6, 2000 DOCUMENTS NAME	GRO	UP ART UNIT	FILING	AD' M		
DOCUMENT NUMBER OTHE Yamagami et	FOREIGN PATE	NAME NT DOCUMENTS	CLASS	SUBCLASS	FILING	DATE		
DOCUMENT NUMBER OTHE Yamagami et	FOREIGN PATE	NT DOCUMENTS	CLASS	SUBCLASS				
OTHE Yamagami et								
OTHE Yamagami et								
OTHE Yamagami et	DATE	COUNTRY						
Yamagami e		*			TRANSL. YES	NO		
Yamagami e				· · · · · · · · · · · · · · · · · · ·				
_		g Author, Title, Date, Pertinent Pa		Y / TO 1 / 1 / 1				
		on of Human Leukemic tides: Implications for th 78-2884, 1996.				or		
Ye et al., "Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation," <i>The EMBO Journal 15</i> (20): 5606-5615, 1996.								
				<u> </u>		7		
								
				,				
900 -								
	-	<u> </u>						
	reference conside	reference considered, whether or not criteria is in a	2/19/2	2/19/2005		2/19/2005		